PD-1及PD-L1抑制剂在前列腺癌治疗中的研究现状

前列腺癌是男性常见的恶性肿瘤，目前主要的治疗手段是根治性前列腺切除术(RP)以及雄激素剥夺疗法(ADT),但两者均有其各自的局限性。近年来免疫治疗发展迅速，其中细胞程序性死亡受体-1(PD-1)及细胞程序性死亡配体-1(PD-L1)作为免疫治疗的理想靶点，其抑制剂在治疗肺癌、结肠癌等多种癌症中发挥了越来越重要的作用。而随着PD-1/PD-L1在前列腺癌方面的研究进展及深入，其在前列腺癌中的作用机制也逐渐明了，PD-1/PD-L1抑制剂在前列腺癌治疗上也将具有广阔的前景。本文将就PD-1及PD-L1在前列腺癌中的表达、作用机制及其抑制剂治疗前列腺癌的相关研究进展作一综述。

Research status of PD-1 and PD-L1 inhibitors in the treatment of prostate cancer

Prostate cancer is a common malignant tumor in men.The current main treatments are radical prostatectomy (RP) and androgen deprivation therapy (ADT),but both have their own limitations.In recent years,immunotherapy has developed rapidly.Among them,programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are ideal targets for immunotherapy,and their inhibitors have played an increasingly important role in the treatment of lung cancer,colon cancer and other cancers.With the progress and in-depth research of PD-1/PD-L1 in prostate cancer,its mechanism of action in prostate cancer has gradually become clear,and PD-1/PD-L1 inhibitors will also have a broad scope prospects for the treatment of prostate cancer.This article will review the expression,mechanism of action of PD-1 and PD-L1 in prostate cancer and related research progress of its inhibitors in the treatment of prostate cancer.